Recently, Yan Zhen Bio and Xi Ji Bio signed a strategic cooperation agreement in Beijing, establishing a partnership for the research, development, and production of Yan Zhen Bio’s regenerative aesthetic products. Under the terms of the agreement, Xi Ji Bio will develop high-end regenerative aesthetic products tailored to Yan Zhen Bio’s needs, accelerate Yan Zhen Bio’s core R&D and production processes, and help Yan Zhen Bio become a leading enterprise in the regenerative aesthetic industry.
This strategic partnership marks a milestone for both parties. At the signing ceremony, both sides expressed their commitment to leveraging this opportunity to combine their strengths, fully utilize their respective advantages in the regenerative aesthetic medicine sector, and jointly advance the industrialization and commercialization of regenerative aesthetic products in China. This collaboration aims to benefit more individuals seeking aesthetic enhancement and usher in a new era of cellular aesthetics. About Yan Zhen Originating from the Tsinghua University EMBA Entrepreneurship Program, the founders have deepened their expertise in the medical and biotechnology sectors for many years, demonstrating exceptional capabilities. With cutting-edge gene and cell technology as its cornerstone, the company upholds the core philosophy of “new life emerging from apoptosis, awakening the infinite potential of cells.” This represents not only a profound understanding of nature’s law of perpetual renewal but also an unwavering pursuit of technology and the beauty industry. As a leader in the field of regenerative aesthetics, Yan Zhen deeply understands that the essence of beauty lies in the health and vitality of cells. We are committed to transforming cutting-edge medical and technological achievements into high-quality lifestyle and beauty products and services accessible to the general public, delivering superior, efficient, and highly cost-effective one-stop beauty solutions that make the beauty of technology available to everyone.
About Xiji Founded in January 2022, Xiji Biotechnology operates under the development philosophy of serving CGT and fostering innovation. It is an innovative translation platform specializing in comprehensive, one-stop CDMO services for cell and gene therapy. Centered on proprietary technology platforms—including genetic engineering, viral vector engineering, and cell engineering—and supported by process development, pilot-scale, and large-scale production capabilities along with a robust quality system, we provide comprehensive technical development and contract manufacturing services for gene and cell therapy companies. These services span from early-stage process research and IND/NDA submissions to commercial-scale production for gene-based, cell-based, and nucleic acid therapeutics. The company operates an 8,000-square-meter GMP facility that complies with multiple international standards, including those of the FDA and NMPA.